Advertisement
"As our lead anti-cancer product candidate, voreloxin, continues todemonstrate promising clinical activity and a consistent safety profile inboth acute myeloid leukemia and ovarian cancer, we are excited to welcome Drs.Steve Ketchum and Mary Bolton to Sunesis," said Daniel Swisher, Sunesis' ChiefExecutive Officer. "We are also pleased to announce the promotions of Drs.Judy Fox and Glenn Michelson. Judy and Glenn have made tremendouscontributions to our voreloxin development program. Collectively, theextensive product development and regulatory expertise of this expandedleadership team will be a tremendous asset as we prepare for the expectedinitiation of late-stage trials for voreloxin next year."
Advertisement
"With the promising clinical activity and safety profile seen to date forvoreloxin, I am excited by the opportunity to lead Sunesis' talenteddevelopment organization as we advance this first-in-class product candidateinto its next phase of development," said Dr. Ketchum.
Dr. Ketchum brings more than fifteen years experience in late-stageproduct development and clinical regulatory strategy, having led the filingsof multiple successful New Drug Applications (NDAs) and supplemental NDAs(sNDAs). He joins Sunesis from Reliant Pharmaceuticals, Inc., where he servedas Senior Vice President, Research & Development and Medical Affairs. In thisrole, he was responsible for the strategic direction and day-to-dayoperations, as well as the organizational growth, of Reliant's clinical R&Dand product development capabilities. Previously, Dr. Ketchum served asSenior Vice President, Operations and Regulatory Affairs for IntraBioticsPharmaceuticals, Inc. from 2002 to 2005, where he was responsible forregulatory affairs, project management, quality assurance, and supply chainmanagement in support of late-stage clinical research. Dr. Ketchum also heldpositions of increasing responsibility in regulatory affairs during his nearlyeight-year tenure at ALZA Corporation from 1994 to 2002, most recently asSenior Director, Regulatory Affairs. He earned a Ph.D. in Pharmacology fromUniversity College London (funded by the Sandoz Institute for MedicalResearch) and a B.S. in Biological Sciences from Stanford University.
Over the past year, Dr. Bolton has served as a consultant to Sunesis onthe development of voreloxin. As a medical oncologist, she brings more than adecade of industry experience in the clinical development of oncologytherapeutics to her new post as Vice President, Clinical Development. From2004 to 2005, Dr. Bolton was Vice President, Clinical Development for SonusPharmaceuticals, Inc. responsible for Phase 1-3 clinical development of thecompany's lead molecule. Before that, she served as Medical Director withZymoGenetics, Inc. and as Medical Director for Cell Therapeutics, Inc.,leading each company's clinical development programs and providing input onregulatory strategy. From 1999 to 2001, Dr. Bolton led the Herceptin(R)post-marketing team at Genentech, Inc., where she served as a ClinicalScientist. Prior to her industry experience, Dr. Bolton spent several yearsas a practicing oncologist, most recently as Assistant Professor of MedicalOncology at the Lombardi Cancer Center, Georgetown University Medical Center.She received her Ph.D. from the Department of Physiology at Johns HopkinsUniversity School of Medicine, her M.
